Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages

International Journal of Cardiology

Volumn 146, Issue 2, 2011, Pages 153-158

  Huang, Zhouqing ^a,b   Wang, Liansheng ^a   Meng, Shu ^a   Wang, Yue ^a   Chen, Ting ^a   Wang, Changqian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Berberine; EMMPRIN; Macrophage; MMP 9

Indexed keywords

BERBERINE; CD147 ANTIGEN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; RNA;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, CD147; ATHEROSCLEROSIS; BERBERINE; CARCINOGENS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE;

EID: 78650657270     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.06.023     Document Type: Article

References (37)

1. J. Shin, J.E. Edelberg, and M.K. Hong Vulnerable atherosclerotic plaque: clinical implications Curr Vasc Pharmacol 1 2003 183 204
2. T.C. Major, L. Liang, X. Lu, W. Rosebury, and T.M. Bocan Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma Arterioscler Thromb Vasc Biol 22 2002 1200 1207
3. N. Watanabe, and U. Ikeda Matrix metalloproteinases and atherosclerosis Curr Atheroscler Rep 6 2004 112 120
4. Z.S. Galis, G.K. Sukhova, R. Kranzhofer, S. Clark, and P. Libby Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases Proc Natl Acad Sci U S A 92 1995 402 406
5. H. Ge, J.F. Zhang, and B.S. Guo Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma Vascul Pharmacol 46 2007 114 121
6. H. Kai, H. Ikeda, and H. Yasukawa Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes J Am Coll Cardiol 32 1998 368 372
7. R. Schmidt, A. Bultmann, and M. Ungerer Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction Circulation 113 2006 834 841
8. J. Zhou, P. Zhu, and J.L. Jiang Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1 BMC Cell Biol 6 2005 25
9. Y.W. Yoon, H.M. Kwon, and K.C. Hwang Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque Atherosclerosis 180 2005 37 44
10. C. Haug, C. Lenz, F. Diaz, and M.G. Bachem Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase inducer (EMMPRIN) release by coronary smooth muscle cells Arterioscler Thromb Vasc Biol 24 2004 1823 1829
11. R. Schmidt, A. Bultmann, and S. Fischel Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes Circ Res 102 2008 302 309
12. M. Ikram A review on the chemical and pharmacological aspects of genus Berberis Planta Med 28 1975 353 358
13. K.V. Anis, N.V. Rajeshkumar, and R. Kuttan Inhibition of chemical carcinogenesis by berberine in rats and mice J Pharm Pharmacol 53 2001 763 768
14. F.R. Stermitz, P. Lorenz, J.N. Tawara, L.A. Zenewicz, and K. Lewis Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor Proc Natl Acad Sci U S A 97 2000 1433 1437
15. S. Tsuchiya, Y. Kobayashi, and Y. Goto Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester Cancer Res 42 1982 1530 1536
16. Z. Huang, C. Wang, and L. Wei Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells Biochem Biophys Res Commun 374 2008 517 521
17. C. Simon, H. Goepfert, and D. Boyd Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion Cancer Res 58 1998 1135 1139
18. A.J. Lusis Atherosclerosis Nature 407 2000 233 241
19. P. Libby Current concepts of the pathogenesis of the acute coronary syndromes Circulation 104 2001 365 372
20. A.C. Newby Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability Arterioscler Thromb Vasc Biol 28 2008 2108 2114
21. A.C. Newby Metalloproteinases and vulnerable atherosclerotic plaques Trends Cardiovasc Med 17 2007 253 258
22. A.K. Death, E.J. Fisher, K.C. McGrath, and D.K. Yue High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes Atherosclerosis 168 2003 263 269
23. N. Fiotti, N. Altamura, and C. Orlando Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI Int J Cardiol 127 2008 350 357
24. N. Kaludercic, M.L. Lindsey, B. Tavazzi, G. Lazzarino, and N. Paolocci Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond Cardiovasc Ther 26 2008 24 37
25. M. Hidalgo, and S.G. Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178 193
26. S. Bellosta, D. Via, and M. Canavesi HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages Arterioscler Thromb Vasc Biol 18 1998 1671 1678
27. N. Ferri, G. Colombo, C. Ferrandi, E.W. Raines, B. Levkau, and A. Corsini Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation Arterioscler Thromb Vasc Biol 27 2007 1043 1049
28. N. Abe, T. Osanai, T. Fujiwara, K. Kameda, T. Matsunaga, and K. Okumura C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin Life Sci 78 2006 1021 1028
29. S.H. Choi, S.K. Cho, and S.S. Kang Effect of apitherapy in piglets with preweaning diarrhea Am J Chin Med 31 2003 321 326
30. J. Yin, H. Xing, and J. Ye Efficacy of berberine in patients with type 2 diabetes mellitus Metabolism 57 2008 712 717
31. S.A. Doggrell Berberine - a novel approach to cholesterol lowering Expert Opin Investig Drugs 14 2005 683 685
32. W. Kong, J. Wei, and P. Abidi Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat Med 10 2004 1344 1351
33. Y.S. Hsieh, W.H. Kuo, and T.W. Lin Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells J Agric Food Chem 55 2007 10437 10445
34. Y.S. Lee, W.S. Kim, and K.H. Kim Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states Diabetes 55 2006 2256 2264
35. F.L. Chen, Z.H. Yang, and Y. Liu Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway Endocrine 33 3 2008 331 337
36. Y. Guo, Q.Z. Wang, and F.M. Li Biochemical pathways in the antiatherosclerotic effect of berberine Chin Med J (Engl) 121 2008 1197 1203
37. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150